Seeking Alpha

Henry McCusker's  Instablog

Henry McCusker
Send Message
Editor and Publisher ... Henry enters his twelve (12) year at RegMed Investors which aggregates, curates and creates bottom-line content of regenerative medicine and cell therapy news providing a "vetted" selection of relevant and high-impact synthesis. He was VP - Strategic Planning... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
  • Athersys (ATHX), Rape, Pillage And Plunder – SELL! 1 comment
    Jan 9, 2013 12:04 PM

    Where's the beef?

    Athersys (NASDAQ: ATHX) has suffered substantial losses throughout 2012 due to a combination of slow progress for the clinical development of their stem cell line MultiStem, as well as share dilution due to the recent offering.

    In the past year the stock price dropped more than … 50% and they diluted the share count more than … 60%. ATHX's stock has lost … 90% of the value in … 5 years.

    With ATHX's stock going nowhere - the Board of directors voted bonuses for their executive:

    • Dr. Gil Van Bokkelen Chief Executive Officer $107,500;
    • William Lehmann, Jr. President and Chief Operating Officer $77,000;
    • Dr. John Harrington Executive Vice President and Chief Scientific Officer $77,800;
    • Dr. Robert Deans Executive Vice President, Regenerative Medicine $62,300;
    • Laura Campbell Vice President of Finance $40,500.

    The Bottom Line: So … rewards are for what - increasing dilution on top of their exorbitant salaries and - some call this a BUY! Shame … no wonder the RegMed universe is going … where? If this isn't a SELL - what is?

    ATHX is trading at $1.18, down -$0.02 or -1.66%.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Back To Henry McCusker's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • Noreika
    , contributor
    Comments (459) | Send Message
     
    Henry, do you plan on doing an article on ACTC? I'd like to hear your analysis on that one. I'm holding a small position, and plan on adding some more as a spec play.
    9 Jan 2013, 02:01 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.